Efficacy and Safety of Finerenone vs. Spironolactone in Patients With Primary Aldosteronism
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 150 participants.
Also called NCT06164379
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 150 participants
- Registry
-
NCT06164379
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Unknown status
Technical summary
Registry record NCT06164379. Randomized; double masking; primary purpose treatment. Start 2023-12-16 (anticipated); primary completion 2024-12-16 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Finerenone vs. Spironolactone in Patients With Primary Aldosteronism
- Acronym
- FAVOR
- Condition
- Primary Aldosteronism
- Intervention (Drug)
- Finerenone
- Intervention (Drug)
- Spironolactone
- Lead sponsor
- Shanghai Jiao Tong University School of Medicine
Record details
- Record id
cardio:ct-nct06164379- Content hash
78f4f325162a822358dd44bdfbf6cb2e8d28f00417491bcb3ac8e18950154e59